Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials

Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials

Background The economic impact of adverse events (AEs) for poly (ADP-ribose) polymerase inhibitors (PARPis) in ovarian or breast cancer has not been widely evaluated.Objective Compare PARPi-related AE management costs from a US payer perspective.Methods The frequency of treatment-related grade 3–4 A...

Full description

Saved in:
Bibliographic Details
Main Authors: Lin Fan, Yuanyuan Zhang, Peter Maguire, Dominic Muston, Matthew Monberg, Jagadeswara Rao Earla, Adela Mihai, Poonam Gulati
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Journal of Market Access & Health Policy
Subjects:
cost analysis
PARP inhibitors
adverse event
advanced ovarian cancer
platinum-sensitive recurrent ovarian cancer
metastatic breast cancer
Online Access:https://www.tandfonline.com/doi/10.1080/20016689.2022.2078474
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/20016689.2022.2078474

Similar Items